文献速递心脑血管急症

经导管主动脉瓣置换术中的脑栓塞保护

Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement.
PubMed 文献 · N Engl J Med · 2022-09-17
一句话结论在经股动脉TAVR患者中,使用脑栓塞保护(CEP)装置未能显著降低围术期卒中发生率(2.3% vs 2.9%,P=0.30),但95%CI不能排除CEP存在获益。

PROTECTED TAVR研究在北美、欧洲和澳大利亚随机纳入3000例主动脉瓣狭窄患者,1:1分为经股动脉TAVR联合CEP组(1501例)与不联合CEP的对照组(1499例),主要终点为TAVR后72小时内或出院前(以先发生者为准)的卒中。CEP组卒中发生率为2.3%,对照组为2.9%,差异为-0.6个百分点(95%CI -1.7至0.5,P=0.30),未达统计学显著。致残性卒中在CEP组为0.5%,对照组为1.3%;死亡、卒中或短暂性脑缺血发作或谵妄、急性肾损伤等指标在两组间无实质差异,CEP入路部位血管并发症仅1例(0.1%)。作者结论认为CEP对围术期卒中发生率无显著影响,但基于该结果周围的95%CI,不能排除CEP在TAVR期间存在获益。

要点

  • 在经股动脉TAVR患者中,CEP组卒中(TAVR后72小时内或出院前)发生率为2.3%,对照组为2.9%,差异-0.6个百分点(95%CI -1.7至0.5,P=0.30),未达统计学显著。
  • 致残性卒中在CEP组为0.5%,在对照组为1.3%。
  • 死亡(CEP组0.5% vs 对照组0.3%)、卒中或短暂性脑缺血发作或谵妄(3.1% vs 3.7%)、急性肾损伤(0.5% vs 0.5%)在两组间无实质差异。
  • CEP装置在尝试置入的1489例中有1406例(94.4%)成功部署;CEP入路部位血管并发症仅1例(0.1%)。
  • 作者结论:CEP对围术期卒中发生率无显著影响,但基于95%CI,结果可能不能排除CEP在TAVR期间的获益。

适用人群与场景

  • 主动脉瓣狭窄并接受经股动脉TAVR的患者,来自北美、欧洲和澳大利亚,随机分组1:1(CEP组1501例,对照组1499例)。
  • 所有患者在基线和TAVR后均由神经科专业人员检查。

处置流程与药物剂量

  • 经股动脉TAVR时随机分配使用CEP装置或不使用CEP装置(对照组)。
  • 在尝试置入CEP装置的患者中,成功部署1406/1489例(94.4%)。

研究设计与关键结果

  • 多中心随机对照试验,共3000例患者随机分组:CEP组1501例,对照组1499例。
  • 主要终点为TAVR后72小时内或出院前(以先发生者为准)的卒中,在意向性治疗人群中分析:CEP组2.3% vs 对照组2.9%,差异-0.6个百分点(95%CI -1.7至0.5,P=0.30),未达统计学显著。
  • 致残性卒中:CEP组0.5% vs 对照组1.3%。
  • 死亡:CEP组0.5% vs 对照组0.3%;卒中、短暂性脑缺血发作或谵妄:CEP组3.1% vs 对照组3.7%;急性肾损伤:CEP组0.5% vs 对照组0.5%。
  • CEP入路部位血管并发症:1例(0.1%)。

证据类型、等级与局限

  • 研究类型:随机对照试验(PROTECTED TAVR,ClinicalTrials.gov NCT04149535),由Boston Scientific资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在经股动脉TAVR的主动脉瓣狭窄患者中,使用CEP对围术期卒中发生率无显著影响,但基于该结果周围的95%CI,不能排除CEP在TAVR期间的获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Transcatheter aortic-valve replacement (TAVR) for the treatment of aortic stenosis can lead to embolization of debris. Capture of debris by devices that provide cerebral embolic protection (CEP) may reduce the risk of stroke.

METHODS: We randomly assigned patients with aortic stenosis in a 1:1 ratio to undergo transfemoral TAVR with CEP (CEP group) or without CEP (control group). The primary end point was stroke within 72 hours after TAVR or before discharge (whichever came first) in the intention-to-treat population. Disabling stroke, death, transient ischemic attack, delirium, major or minor vascular complications at the CEP access site, and acute kidney injury were also assessed. A neurology professional examined all the patients at baseline and after TAVR.

RESULTS: A total of 3000 patients across North America, Europe, and Australia underwent randomization; 1501 were assigned to the CEP group and 1499 to the control group. A CEP device was successfully deployed in 1406 of the 1489 patients (94.4%) in whom an attempt was made. The incidence of stroke within 72 hours after TAVR or before discharge did not differ significantly between the CEP group and the control group (2.3% vs. 2.9%; difference, -0.6 percentage points; 95% confidence interval, -1.7 to 0.5; P = 0.30). Disabling stroke occurred in 0.5% of the patients in the CEP group and in 1.3% of those in the control group. There were no substantial differences between the CEP group and the control group in the percentage of patients who died (0.5% vs. 0.3%); had a stroke, a transient ischemic attack, or delirium (3.1% vs. 3.7%); or had acute kidney injury (0.5% vs. 0.5%). One patient (0.1%) had a vascular complication at the CEP access site.

CONCLUSIONS: Among patients with aortic stenosis undergoing transfemoral TAVR, the use of CEP did not have a significant effect on the incidence of periprocedural stroke, but on the basis of the 95% confidence interval around this outcome, the results may not rule out a benefit of CEP during TAVR. (Funded by Boston Scientific; PROTECTED TAVR ClinicalTrials.gov number, NCT04149535.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Kapadia SR, Makkar R, Leon M, et al. Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement. N Engl J Med. 2022. PMID: 36121045. doi:10.1056/NEJMoa2204961

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。